Life Science Investing Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
Life Science Investing Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
Life Science Investing Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
Life Science Investing Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Life Science Investing Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
Life Science Investing Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
Life Science Investing Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
life science investing Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
life science investing Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
life science investing Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
life science investing Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
Torchlight Innovations (Doing Business as RZOLV Technologies) Announces Preliminary Positive Results on Rare Earth and Critical Mineral Recoveries
